Inhibition of protein kinase C by resveratrol

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1637, Issue 1, 2003, Pages 59-69

  Slater, Simon J ^a   Seiz, Jodie L ^a   Cook, Anthony C ^a   Stagliano, Brigid A ^a   Buzas, Christopher J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Protein kinase C; Resveratrol

Indexed keywords

CALCIUM ION; DIACYLGLYCEROL; ISOENZYME; MEMBRANE LIPID; PHORBOL ESTER; PHOSPHATIDYLSERINE; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; RESVERATROL;

ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR FUNCTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 0037454696     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(02)00214-4     Document Type: Article

References (78)

1. O'Keefe J.H. Jr., Lavie C.J. Jr., McCallister B.D. Insights into the pathogenesis and prevention of coronary artery disease. Mayo Clin. Proc. 70:1995;69-79.
2. Van Schooten F.J., Hirvonen A., Maas L.M., De Mol B.A., Kleinjans J.C., Bell D.A., Durrer J.D. Putative susceptibility markers of coronary artery disease: association between vdr genotype, smoking, and aromatic DNA adduct levels in human right atrial tissue. FASEB J. 12:1998;1409-1417.
3. Burke A.P., Farb A., Malcom G.T., Liang Y.H., Smialek J., Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N. Engl. J. Med. 336:1997;1276-1282.
4. Constant J. Alcohol, ischemic heart disease, and the french paradox. Coron. Artery Dis. 8:1997;645-649.
5. Renaud S., de Lorgeril M. Wine, alcohol, platelets, and the french paradox for coronary heart disease. Lancet. 339:1992;1523-1526.
6. Wu J.M., Wang Z.R., Hsieh T.C., Bruder J.L., Zou J.G., Huang Y.Z. Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine (review). Int. J. Mol. Med. 8:2001;3-17.
7. Klatsky A.L., Armstrong M.A., Friedman G.D. Red wine, white wine, liquor, beer, and risk for coronary artery disease hospitalization. Am. J. Cardiol. 80:1997;416-420.
8. Gaziano J.M., Hennekens C.H., Godfried S.L., Sesso H.D., Glynn R.J., Breslow J.L., Buring J.E. Type of alcoholic beverage and risk of myocardial infarction. Am. J. Cardiol. 83:1999;52-57.
9. Klatsky A.L., Friedman G.D., Siegelaub A.B. Alcohol consumption before myocardial infarction. Results from the kaiser-permanente epidemiologic study of myocardial infarction. Ann. Intern. Med. 81:1974;294-301.
10. Das D.K., Sato M., Ray P.S., Maulik G., Engelman R.M., Bertelli A.A., Bertelli A. Cardioprotection of red wine: role of polyphenolic antioxidants. Drugs Exp. Clin. Res. 25:1999;115-120.
11. Burr M.L. Explaining the french paradox. J. R. Soc. Health. 115:1995;217-219.
12. Rimm E.B., Klatsky A., Grobbee D., Stampfer M.J. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits. BMJ. 312:1996;731-736.
13. Criqui M.H., Ringel B.L. Does diet or alcohol explain the french paradox? Lancet. 344:1994;1719-1723.
14. St. Leger A.S., Cochrane A.L., Moore F. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. Lancet. 1:1979;1017-1020.
15. Ulbricht T.L., Southgate D.A. Coronary heart disease: seven dietary factors. Lancet. 338:1991;985-992.
16. Goldberg D.M., Hahn S.E., Parkes J.G. Beyond alcohol: beverage consumption and cardiovascular mortality. Clin. Chim. Acta. 237:1995;155-187.
17. Meister K.A., Whelan E.M., Kava R. The health effects of moderate alcohol intake in humans: an epidemiologic review. Crit. Rev. Clin. Lab. Sci. 37:2000;261-296.
18. Sato M., Maulik N., Das D.K. Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants. Ann. N. Y. Acad. Sci. 957:2002;122-135.
19. Fitzpatrick D.F., Hirschfield S.L., Coffey R.G. Endothelium-dependent vasorelaxing activity of wine and other grape products. Am. J. Physiol. 265:1993;H774-H778.
20. Frankel E.N., Kanner J., German J.B., Parks E., Kinsella J.E. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet. 341:1993;454-457.
21. Kondo K., Matsumoto A., Kurata H., Tanahashi H., Koda H., Amachi T., Itakura H. Inhibition of oxidation of low-density lipoprotein with red wine. Lancet. 344:1994;1152.
22. Orallo F., Alvarez E., Camina M., Leiro J.M., Gomez E., Fernandez P. The possible implication of trans-resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol. Pharmacol. 61:2002;294-302.
23. Pace-Asciak C.R., Hahn S., Diamandis E.P., Soleas G., Goldberg D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin. Chim. Acta. 235:1995;207-219.
24. Pace-Asciak C.R., Rounova O., Hahn S.E., Diamandis E.P., Goldberg D.M. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin. Chim. Acta. 246:1996;163-182.
25. Wang Z., Zou J., Huang Y., Cao K., Xu Y., Wu J.M. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin. Med. J. (Engl.). 115:2002;378-380.
26. Jang D.S., Kang B.S., Ryu S.Y., Chang I.M., Min K.R., Kim Y. Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen radical production. Biochem. Pharmacol. 57:1999;705-712.
27. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:1989;915-924.
28. Ferrero M.E., Bertelli A.E., Fulgenzi A., Pellegatta F., Corsi M.M., Bonfrate M., Ferrara F., De Caterina R., Giovannini L., Bertelli A. Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am. J. Clin. Nutr. 68:1998;1208-1214.
29. Belguendouz L., Fremont L., Linard A. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem. Pharmacol. 53:1997;1347-1355.
30. Chanvitayapongs S., Draczynska-Lusiak B., Sun A.Y. Amelioration of oxidative stress by antioxidants and resveratrol in pc12 cells. NeuroReport. 8:1997;1499-1502.
31. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:1997;218-220.
32. Jang M., Pezzuto J.M. Cancer chemopreventive activity of resveratrol. Drugs Exp. Clin. Res. 25:1999;65-77.
33. Zhong M., Cheng G.F., Wang W.J., Guo Y., Zhu X.Y., Zhang J.T. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine. 6:1999;79-84.
34. Tsai S.H., Lin-Shiau S.Y., Lin J.K. Suppression of nitric oxide synthase and the down-regulation of the activation of NFκB in macrophages by resveratrol. Br. J. Pharmacol. 126:1999;673-680.
35. Hsieh T.C., Juan G., Darzynkiewicz Z., Wu J.M. Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21(waf1/cip1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res. 59:1999;2596-2601.
36. Mitchell S.H., Zhu W., Young C.Y. Resveratrol inhibits the expression and function of the androgen receptor in lncap prostate cancer cells. Cancer Res. 59:1999;5892-5895.
37. Bruder J.L., Hsieh Tc T., Lerea K.M., Olson S.C., Wu J.M. Induced cytoskeletal changes in bovine pulmonary artery endothelial cells by resveratrol and the accompanying modified responses to arterial shear stress. BMC Cell Biol. 2:2001;1.
38. El-Mowafy A.M., White R.E. Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects. FEBS Lett. 451:1999;63-67.
39. Subbaramaiah K., Chung W.J., Michaluart P., Telang N., Tanabe T., Inoue H., Jang M., Pezzuto J.M., Dannenberg A.J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 273:1998;21875-21882.
40. Yu R., Hebbar V., Kim D.W., Mandlekar S., Pezzuto J.M., Kong A.N. Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. Mol. Pharmacol. 60:2001;217-224.
41. Newton A.C. Regulation of protein kinase C. Curr. Opin. Cell Biol. 9:1997;161-167.
42. Jayatilake G.S., Jayasuriya H., Lee E.S., Koonchanok N.M., Geahlen R.L., Ashendel C.L., McLaughlin J.L., Chang C.J. Kinase inhibitors from Polygonum cuspidatum. J. Nat. Prod. 56:1993;1805-1810.
43. Stewart J.R., Ward N.E., Ioannides C.G., O'Brian C.A. Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. Biochemistry. 38:1999;13244-13251.
44. Stewart J.R., Christman K.L., O'Brian C.A. Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase cd but not protein kinase C isozyme autophosphorylation. Biochem. Pharmacol. 60:2000;1355-1359.
45. Garcia-Garcia J., Micol V., de Godos A., Gomez-Fernandez J.C. The cancer chemopreventive agent resveratrol is incorporated into model membranes and inhibits protein kinase C α activity. Arch. Biochem. Biophys. 372:1999;382-388.
46. Atten M.J., Attar B.M., Milson T., Holian O. Resveratrol-induced inactivation of human gastric adenocarcinoma cells through a protein kinase C-mediated mechanism. Biochem. Pharmacol. 62:2001;1423-1432.
47. Chen C.K., Pace-Asciak C.R. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen. Pharmacol. 27:1996;363-366.
48. Kimura Y., Okuda H., Arichi S. Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim. Biophys. Acta. 834:1985;275-278.
49. Shan C.W., Yang S.Q., He H.D., Shao S.L., Zhang P.W. Influences of 3,4,5-trihydroxystibene-3-beta-mono-d-glucoside on rabbits' platelet aggregation and thromboxane b2 production in vitro. Zhongguo YaoLi XueBao. 11:1990;527-530.
50. Stabel S., Schaap D., Parker P.J. Expression of protein kinase C isotypes using baculovirus vectors. Methods Enzymol. 200:1991;670-673.
51. Slater S.J., Kelly M.B., Taddeo F.J., Rubin E., Stubbs C.D. Evidence for discrete diacylglycerol and phorbol ester binding sites on protein kinase C. J. Biol. Chem. 269:1994;17160-17165.
52. F.J. Taddeo, Cloning, Expression and Purification of Protein Kinase C: A Comparative Study of the Modes of Activation of Protein Kinase C, PhD thesis, Department of Pathology and Cell Biology, Thomas Jefferson University, Philadelphia, 1998.
53. Slater S.J., Taddeo F.J., Mazurek A., Stagliano B.A., Milano S.K., Kelly M.B., Ho C., Stubbs C.D. Inhibition of membrane lipid-independent protein kinase C α activity by phorbol esters, diacylglycerols, and bryostatin-1. J. Biol. Chem. 273:1998;23160-23168.
54. Slater S.J., Kelly M.B., Taddeo F.J., Ho C., Rubin E., Stubbs C.D. The modulation of protein kinase C activity by membrane lipid bilayer structure. J. Biol. Chem. 269:1994;4866-4871.
55. House C., Kemp B.E. Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. Science. 238:1987;1726-1728.
56. Saido T.C., Mizuno K., Konno Y., Osada S.I., Ohno S., Suzuki K. Purification and characterization of protein kinase C ε from rabbit brain. Biochemistry. 31:1992;482-490.
57. Ohno S., Akita Y., Konno Y., Imajoh S., Suzuki K. A novel phorbol ester receptor/protein kinase, nPKC, distantly related to the protein kinase C family. Cell. 53:1988;731-741.
58. MacDonald R.C., MacDonald R.I., Menco B.P., Takeshita K., Subbarao N.K., Hu L.R. Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim. Biophys. Acta. 1061:1991;297-303.
59. Fabriato A., Fabriato F. J. Physiol. (Lond., Print). 75:1979;463-505.
60. Epand R.M., Leon B.T. Hexagonal phase forming propensity detected in phospholipid bilayers with fluorescent probes. Biochemistry. 31:1992;1550-1554.
61. Slater S.J., Milano S.K., Stagliano B.A., Gergich K.J., Ho C., Mazurek A., Taddeo F.J., Kelly M.B., Yeager M.D., Stubbs C.D. Synergistic activation of protein kinase Cα, -βI, and -γ isoforms induced by diacylglycerol and phorbol ester: roles of membrane association and activating conformational changes. Biochemistry. 38:1999;3804-3815.
62. Mosior M., Epand R.M. Mechanism of activation of protein kinase C: roles of diolein and phosphatidylserine. Biochemistry. 32:1993;66-75.
63. Mosior M., Newton A.C. Mechanism of the apparent cooperativity in the interaction of protein kinase C with phosphatidylserine. Biochemistry. 37:1998;17271-17279.
64. Mosior M., Newton A.C. Mechanism of interaction of protein kinase C with phorbol esters: reversibility and nature of membrane association. J. Biol. Chem. 270:1996;25526-25533.
65. Newton A.C., Johnson J.E. Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. Biochim. Biophys. Acta. 1376:1998;155-172.
66. Zhang G., Kazanietz M.G., Blumberg P.M., Hurley J.H. Crystal structure of the cys2 activator-binding domain of protein kinase C δ in complex with phorbol ester. Cell. 81:1995;917-924.
67. Ho C., Slater S.J., Stagliano B.A., Stubbs C.D. Conformation of the C1 phorbol-ester-binding domain participates in the activating conformational change of protein kinase C. Biochem. J. 344(Pt. 2):1999;451-460.
68. Ways D.K., Cook P.P., Webster C., Parker P.J. Effect of phorbol esters on protein kinase C ζ J. Biol. Chem. 267:1992;4799-4805.
69. Hurley J.H., Newton A.C., Parker P.J., Blumberg P.M., Nishizuka Y. Taxonomy and function of C1 protein kinase C homology domains. Protein Sci. 6:1997;477-480.
70. Wang S., Kazanietz M.G., Blumberg P.M., Marquez V.E., Milne G.W. Molecular modeling and site-directed mutagenesis studies of a phorbol ester-binding site in protein kinase C. J. Med. Chem. 39:1996;2541-2553.
71. Kazanietz M.G., Wang S., Milne G.W.A., Lewin N.E., Liu H.L., Blumberg P.M. Residues in the second cysteine-rich region of protein kinase C δ relevant to phorbol ester binding as revealed by site-directed mutagenesis. J. Biol. Chem. 270:1995;21852-21859.
72. Slater S.J., Kelly M.B., Larkin J.D., Ho C., Mazurek A., Taddeo F.J., Yeager M.D., Stubbs C.D. Interaction of alcohols and anesthetics with protein kinase C α J. Biol. Chem. 272:1997;6167-6173.
73. Haworth R.S., Avkiran M. Inhibition of protein kinase D by resveratrol. Biochem. Pharmacol. 62:2001;1647-1651.
74. Mgbonyebi O.P., Russo J., Russo I.H. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int. J. Oncol. 12:1998;865-869.
75. Bertelli A., Bertelli A.A., Gozzini A., Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp. Clin. Res. 24:1998;133-138.
76. Bertelli A.A., Giovannini L., Stradi R., Urien S., Tillement J.P., Bertelli A. Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats. Drugs Exp. Clin. Res. 24:1998;51-55.
77. Bertelli A.A., Giovannini L., Stradi R., Bertelli A., Tillement J.P. Plasma, urine and tissue levels of trans- and cis-resveratrol (3,4′,5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int. J. Tissue React. 18:1996;67-71.
78. Bertelli A.A., Giovannini L., Stradi R., Urien S., Tillement J.P., Bertelli A. Kinetics of trans- and cis-resveratrol (3,4′,5-trihydroxystilbene) after red wine oral administration in rats. Int. J. Clin. Pharmacol. Res. 16:1996;77-81.